25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

AnaptysBio Inc
Buy, Hold or Sell?

Let's analyze Anaptysbio together

I guess you are interested in AnaptysBio Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of AnaptysBio Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about AnaptysBio Inc

I send you an email if I find something interesting about AnaptysBio Inc.

1. Quick Overview

1.1. Quick analysis of Anaptysbio (30 sec.)










1.2. What can you expect buying and holding a share of Anaptysbio? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
5.0%

What is your share worth?

Current worth
$2.77
Expected worth in 1 year
$1.59
How sure are you?
27.5%

+ What do you gain per year?

Total Gains per Share
$-1.18
Return On Investment
-5.2%

For what price can you sell your share?

Current Price per Share
$22.88
Expected price per share
$18.03 - $30.81
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Anaptysbio (5 min.)




Live pricePrice per Share (EOD)
$22.88
Intrinsic Value Per Share
$-28.53 - $-18.98
Total Value Per Share
$-25.76 - $-16.20

2.2. Growth of Anaptysbio (5 min.)




Is Anaptysbio growing?

Current yearPrevious yearGrowGrow %
How rich?$84.3m$180.5m-$122.9m-213.8%

How much money is Anaptysbio making?

Current yearPrevious yearGrowGrow %
Making money-$41.4m-$38m-$3.4m-8.2%
Net Profit Margin-403.9%-1,547.5%--

How much money comes from the company's main activities?

2.3. Financial Health of Anaptysbio (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#375 / 945

Most Revenue
#241 / 945

Most Profit
#808 / 945

Most Efficient
#603 / 945
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Anaptysbio?

Welcome investor! Anaptysbio's management wants to use your money to grow the business. In return you get a share of Anaptysbio.

First you should know what it really means to hold a share of Anaptysbio. And how you can make/lose money.

Speculation

The Price per Share of Anaptysbio is $22.88. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Anaptysbio.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Anaptysbio, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $2.77. Based on the TTM, the Book Value Change Per Share is $-0.30 per quarter. Based on the YOY, the Book Value Change Per Share is $-1.29 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Anaptysbio.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-1.08-4.7%-1.36-5.9%-1.21-5.3%-0.84-3.7%-0.56-2.4%
Usd Book Value Change Per Share2.4510.7%-0.30-1.3%-1.29-5.6%-0.55-2.4%0.070.3%
Usd Dividend Per Share0.000.0%0.000.0%0.030.1%0.010.0%0.000.0%
Usd Total Gains Per Share2.4510.7%-0.30-1.3%-1.26-5.5%-0.55-2.4%0.070.3%
Usd Price Per Share33.50-25.63-22.76-23.12-28.82-
Price to Earnings Ratio-7.76--4.90--5.05--29.51--19.51-
Price-to-Total Gains Ratio13.68--10.91--26.28--33.04--77.20-
Price to Book Ratio12.08-27.75-3.94-7.49-5.60-
Price-to-Total Gains Ratio13.68--10.91--26.28--33.04--77.20-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share22.88
Number of shares43
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.01
Usd Book Value Change Per Share-0.30-0.55
Usd Total Gains Per Share-0.30-0.55
Gains per Quarter (43 shares)-12.72-23.50
Gains per Year (43 shares)-50.90-94.02
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-51-611-95-104
20-102-1122-190-198
30-153-1633-285-292
40-204-2144-380-386
50-254-2655-476-480
60-305-3167-571-574
70-356-3678-666-668
80-407-4189-761-762
90-458-46910-856-856
100-509-52011-951-950

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%1.019.00.05.0%4.036.00.010.0%5.036.01.011.9%
Book Value Change Per Share1.03.00.025.0%1.011.00.08.3%3.017.00.015.0%11.028.01.027.5%12.029.01.028.6%
Dividend per Share0.00.04.00.0%2.00.010.016.7%2.00.018.010.0%2.00.038.05.0%2.00.040.04.8%
Total Gains per Share1.03.00.025.0%1.011.00.08.3%3.017.00.015.0%11.028.01.027.5%12.029.01.028.6%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of AnaptysBio Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--2.448-0.296+112%-1.292+153%-0.553+123%0.069+3433%
Book Value Per Share--2.7731.891+47%5.932-53%8.736-68%7.436-63%
Current Ratio--10.22510.427-2%12.709-20%17.179-40%14.212-28%
Debt To Asset Ratio--0.8290.873-5%0.673+23%0.433+91%0.336+147%
Debt To Equity Ratio--4.84814.685-67%2.187+122%3.597+35%2.108+130%
Dividend Per Share----0%0.032-100%0.006-100%0.003-100%
Enterprise Value--1040427450.000774135187.500+34%760221533.750+37%890673022.700+17%1349470048.935-23%
Eps---1.080-1.361+26%-1.214+12%-0.844-22%-0.560-48%
Ev To Ebitda Ratio---15.444-7.408-52%-6.436-58%27.792-156%0.545-2931%
Ev To Sales Ratio--8.66516.775-48%66.275-87%infnan%infnan%
Free Cash Flow Per Share---0.333-0.849+155%-0.804+142%-0.562+69%-0.393+18%
Free Cash Flow To Equity Per Share--2.008-0.074+104%-1.233+161%-0.011+101%0.322+524%
Gross Profit Margin--1.0001.0050%1.0000%1.0010%1.0000%
Intrinsic Value_10Y_max---18.977--------
Intrinsic Value_10Y_min---28.528--------
Intrinsic Value_1Y_max---1.620--------
Intrinsic Value_1Y_min---3.140--------
Intrinsic Value_3Y_max---5.083--------
Intrinsic Value_3Y_min---9.246--------
Intrinsic Value_5Y_max---8.804--------
Intrinsic Value_5Y_min---15.100--------
Market Cap696208656.000-46%1019361450.000779735437.500+31%692633283.750+47%703541972.700+45%877038812.925+16%
Net Profit Margin---1.094-4.039+269%-15.475+1314%-11.027+908%-6.012+449%
Operating Margin---0.581-3.303+469%-14.074+2323%-9.393+1517%-5.159+788%
Operating Ratio--1.7784.566-61%15.993-89%10.957-84%7.109-75%
Pb Ratio8.252-46%12.08227.753-56%3.943+206%7.487+61%5.601+116%
Pe Ratio-5.298+32%-7.757-4.901-37%-5.053-35%-29.515+280%-19.512+152%
Price Per Share22.880-46%33.50025.625+31%22.763+47%23.121+45%28.823+16%
Price To Free Cash Flow Ratio-17.190+32%-25.169-11.743-53%-9.543-62%-8.028-68%-19.005-24%
Price To Total Gains Ratio9.347-46%13.685-10.905+180%-26.275+292%-33.040+341%-77.196+664%
Quick Ratio--15.51617.986-14%23.260-33%25.827-40%21.157-27%
Return On Assets---0.067-0.094+42%-0.071+7%-0.053-20%-0.043-35%
Return On Equity---0.389-1.628+318%-0.233-40%-0.404+4%-0.222-43%
Total Gains Per Share--2.448-0.296+112%-1.260+151%-0.547+122%0.072+3278%
Usd Book Value--84367000.00057531750.000+47%180507250.000-53%265826000.000-68%228092975.000-63%
Usd Book Value Change Per Share--2.448-0.296+112%-1.292+153%-0.553+123%0.069+3433%
Usd Book Value Per Share--2.7731.891+47%5.932-53%8.736-68%7.436-63%
Usd Dividend Per Share----0%0.032-100%0.006-100%0.003-100%
Usd Enterprise Value--1040427450.000774135187.500+34%760221533.750+37%890673022.700+17%1349470048.935-23%
Usd Eps---1.080-1.361+26%-1.214+12%-0.844-22%-0.560-48%
Usd Free Cash Flow---10125000.000-25847250.000+155%-24459500.000+142%-17111950.000+69%-12096350.000+19%
Usd Free Cash Flow Per Share---0.333-0.849+155%-0.804+142%-0.562+69%-0.393+18%
Usd Free Cash Flow To Equity Per Share--2.008-0.074+104%-1.233+161%-0.011+101%0.322+524%
Usd Market Cap696208656.000-46%1019361450.000779735437.500+31%692633283.750+47%703541972.700+45%877038812.925+16%
Usd Price Per Share22.880-46%33.50025.625+31%22.763+47%23.121+45%28.823+16%
Usd Profit---32851000.000-41414500.000+26%-38002750.000+16%-26555000.000-19%-17726525.000-46%
Usd Revenue--30017000.00014293000.000+110%3740000.000+703%10839300.000+177%7118650.000+322%
Usd Total Gains Per Share--2.448-0.296+112%-1.260+151%-0.547+122%0.072+3278%
 EOD+2 -6MRQTTM+32 -6YOY+25 -145Y+21 -1810Y+18 -21

3.3 Fundamental Score

Let's check the fundamental score of AnaptysBio Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-5.298
Price to Book Ratio (EOD)Between0-18.252
Net Profit Margin (MRQ)Greater than0-1.094
Operating Margin (MRQ)Greater than0-0.581
Quick Ratio (MRQ)Greater than115.516
Current Ratio (MRQ)Greater than110.225
Debt to Asset Ratio (MRQ)Less than10.829
Debt to Equity Ratio (MRQ)Less than14.848
Return on Equity (MRQ)Greater than0.15-0.389
Return on Assets (MRQ)Greater than0.05-0.067
Total3/10 (30.0%)

3.4 Technical Score

Let's check the technical score of AnaptysBio Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5045.706
Ma 20Greater thanMa 5022.383
Ma 50Greater thanMa 10027.119
Ma 100Greater thanMa 20031.355
OpenGreater thanClose24.860
Total2/5 (40.0%)

4. In-depth Analysis

4.1 About AnaptysBio Inc

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

Fundamental data was last updated by Penke on 2024-12-05 12:24:03.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is just able to pay all its debts by selling its assets.
The company is unable to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Anaptysbio earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Anaptysbio to the Biotechnology industry mean.
  • A Net Profit Margin of -109.4% means that $-1.09 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of AnaptysBio Inc:

  • The MRQ is -109.4%. The company is making a huge loss. -2
  • The TTM is -403.9%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-109.4%TTM-403.9%+294.4%
TTM-403.9%YOY-1,547.5%+1,143.6%
TTM-403.9%5Y-1,102.7%+698.8%
5Y-1,102.7%10Y-601.2%-501.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-109.4%-109.4%0.0%
TTM-403.9%-221.4%-182.5%
YOY-1,547.5%-208.7%-1,338.8%
5Y-1,102.7%-346.2%-756.5%
10Y-601.2%-470.4%-130.8%
4.3.1.2. Return on Assets

Shows how efficient Anaptysbio is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Anaptysbio to the Biotechnology industry mean.
  • -6.7% Return on Assets means that Anaptysbio generated $-0.07 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of AnaptysBio Inc:

  • The MRQ is -6.7%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -9.4%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-6.7%TTM-9.4%+2.8%
TTM-9.4%YOY-7.1%-2.3%
TTM-9.4%5Y-5.3%-4.1%
5Y-5.3%10Y-4.3%-1.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-6.7%-11.6%+4.9%
TTM-9.4%-12.0%+2.6%
YOY-7.1%-11.2%+4.1%
5Y-5.3%-12.6%+7.3%
10Y-4.3%-14.2%+9.9%
4.3.1.3. Return on Equity

Shows how efficient Anaptysbio is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Anaptysbio to the Biotechnology industry mean.
  • -38.9% Return on Equity means Anaptysbio generated $-0.39 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of AnaptysBio Inc:

  • The MRQ is -38.9%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -162.8%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-38.9%TTM-162.8%+123.8%
TTM-162.8%YOY-23.3%-139.5%
TTM-162.8%5Y-40.4%-122.3%
5Y-40.4%10Y-22.2%-18.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-38.9%-14.5%-24.4%
TTM-162.8%-16.0%-146.8%
YOY-23.3%-14.6%-8.7%
5Y-40.4%-18.6%-21.8%
10Y-22.2%-19.3%-2.9%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of AnaptysBio Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Anaptysbio is operating .

  • Measures how much profit Anaptysbio makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Anaptysbio to the Biotechnology industry mean.
  • An Operating Margin of -58.1% means the company generated $-0.58  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of AnaptysBio Inc:

  • The MRQ is -58.1%. The company is operating very inefficient. -2
  • The TTM is -330.3%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-58.1%TTM-330.3%+272.2%
TTM-330.3%YOY-1,407.4%+1,077.1%
TTM-330.3%5Y-939.3%+609.0%
5Y-939.3%10Y-515.9%-423.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-58.1%-203.3%+145.2%
TTM-330.3%-316.3%-14.0%
YOY-1,407.4%-216.5%-1,190.9%
5Y-939.3%-378.6%-560.7%
10Y-515.9%-480.3%-35.6%
4.3.2.2. Operating Ratio

Measures how efficient Anaptysbio is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 1.78 means that the operating costs are $1.78 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of AnaptysBio Inc:

  • The MRQ is 1.778. The company is inefficient in keeping operating costs low. -1
  • The TTM is 4.566. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.778TTM4.566-2.788
TTM4.566YOY15.993-11.428
TTM4.5665Y10.957-6.392
5Y10.95710Y7.109+3.848
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.7782.284-0.506
TTM4.5663.198+1.368
YOY15.9933.263+12.730
5Y10.9574.651+6.306
10Y7.1096.419+0.690
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of AnaptysBio Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Anaptysbio is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 10.23 means the company has $10.23 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of AnaptysBio Inc:

  • The MRQ is 10.225. The company is very able to pay all its short-term debts. +2
  • The TTM is 10.427. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ10.225TTM10.427-0.202
TTM10.427YOY12.709-2.281
TTM10.4275Y17.179-6.751
5Y17.17910Y14.212+2.967
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ10.2253.601+6.624
TTM10.4273.872+6.555
YOY12.7094.655+8.054
5Y17.1795.973+11.206
10Y14.2126.258+7.954
4.4.3.2. Quick Ratio

Measures if Anaptysbio is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Anaptysbio to the Biotechnology industry mean.
  • A Quick Ratio of 15.52 means the company can pay off $15.52 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of AnaptysBio Inc:

  • The MRQ is 15.516. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 17.986. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ15.516TTM17.986-2.469
TTM17.986YOY23.260-5.275
TTM17.9865Y25.827-7.842
5Y25.82710Y21.157+4.670
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ15.5163.093+12.423
TTM17.9863.416+14.570
YOY23.2604.393+18.867
5Y25.8275.954+19.873
10Y21.1576.436+14.721
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of AnaptysBio Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Anaptysbio assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Anaptysbio to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.83 means that Anaptysbio assets are financed with 82.9% credit (debt) and the remaining percentage (100% - 82.9%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of AnaptysBio Inc:

  • The MRQ is 0.829. The company is just able to pay all its debts by selling its assets.
  • The TTM is 0.873. The company is just able to pay all its debts by selling its assets.
Trends
Current periodCompared to+/- 
MRQ0.829TTM0.873-0.044
TTM0.873YOY0.673+0.201
TTM0.8735Y0.433+0.440
5Y0.43310Y0.336+0.097
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.8290.345+0.484
TTM0.8730.346+0.527
YOY0.6730.311+0.362
5Y0.4330.365+0.068
10Y0.3360.382-0.046
4.5.4.2. Debt to Equity Ratio

Measures if Anaptysbio is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Anaptysbio to the Biotechnology industry mean.
  • A Debt to Equity ratio of 484.8% means that company has $4.85 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of AnaptysBio Inc:

  • The MRQ is 4.848. The company is unable to pay all its debts with equity. -1
  • The TTM is 14.685. The company is unable to pay all its debts with equity. -1
Trends
Current periodCompared to+/- 
MRQ4.848TTM14.685-9.836
TTM14.685YOY2.187+12.498
TTM14.6855Y3.597+11.087
5Y3.59710Y2.108+1.489
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.8480.393+4.455
TTM14.6850.431+14.254
YOY2.1870.384+1.803
5Y3.5970.452+3.145
10Y2.1080.497+1.611
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Anaptysbio generates.

  • Above 15 is considered overpriced but always compare Anaptysbio to the Biotechnology industry mean.
  • A PE ratio of -7.76 means the investor is paying $-7.76 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of AnaptysBio Inc:

  • The EOD is -5.298. Based on the earnings, the company is expensive. -2
  • The MRQ is -7.757. Based on the earnings, the company is expensive. -2
  • The TTM is -4.901. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-5.298MRQ-7.757+2.459
MRQ-7.757TTM-4.901-2.857
TTM-4.901YOY-5.053+0.152
TTM-4.9015Y-29.515+24.614
5Y-29.51510Y-19.512-10.003
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-5.298-2.259-3.039
MRQ-7.757-2.480-5.277
TTM-4.901-3.148-1.753
YOY-5.053-3.244-1.809
5Y-29.515-5.991-23.524
10Y-19.512-6.692-12.820
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of AnaptysBio Inc:

  • The EOD is -17.190. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -25.169. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -11.743. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-17.190MRQ-25.169+7.979
MRQ-25.169TTM-11.743-13.426
TTM-11.743YOY-9.543-2.201
TTM-11.7435Y-8.028-3.716
5Y-8.02810Y-19.005+10.977
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-17.190-2.995-14.195
MRQ-25.169-3.289-21.880
TTM-11.743-3.668-8.075
YOY-9.543-4.472-5.071
5Y-8.028-8.001-0.027
10Y-19.005-9.190-9.815
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Anaptysbio is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 12.08 means the investor is paying $12.08 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of AnaptysBio Inc:

  • The EOD is 8.252. Based on the equity, the company is overpriced. -1
  • The MRQ is 12.082. Based on the equity, the company is expensive. -2
  • The TTM is 27.753. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD8.252MRQ12.082-3.830
MRQ12.082TTM27.753-15.670
TTM27.753YOY3.943+23.810
TTM27.7535Y7.487+20.266
5Y7.48710Y5.601+1.886
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD8.2522.001+6.251
MRQ12.0822.054+10.028
TTM27.7532.385+25.368
YOY3.9432.431+1.512
5Y7.4873.690+3.797
10Y5.6014.307+1.294
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of AnaptysBio Inc.

4.8.1. Institutions holding AnaptysBio Inc

Institutions are holding 111.582% of the shares of AnaptysBio Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-09-30EcoR1 Capital, LLC25.61738.938177949962739723.6427
2024-09-30FMR Inc10.87520.0068330917543855715.2774
2024-06-30BlackRock Inc5.81670.0011769944498932.9007
2024-09-30Vanguard Group Inc5.58730.001170015627575019.3589
2024-09-30TANG CAPITAL MANAGEMENT LLC4.37383.1849133087900
2024-09-30Boxer Capital LLC4.27232.1371130000000
2024-09-30First Light Asset Management, LLC3.11592.642694813116897321.6866
2024-09-30T. Rowe Price Associates, Inc.3.03370.0036923117622893207.4761
2024-09-30State Street Corp2.97810.0012906182-60670-6.275
2024-09-30Palo Alto Investors, LLC2.77363.6725843971403305.0184
2024-09-30Mangrove Partners2.2661.985768952100
2024-09-30Assenagon Asset Management SA1.56250.029347544616881355.0538
2024-09-30Geode Capital Management, LLC1.52950.0013465401133362.95
2024-09-30Woodline Partners LP1.51170.129845997920761382.2666
2024-09-305AM Venture Management, LLC1.17562.47635773300
2024-09-30Franklin Resources Inc1.16460.0034354370-111003-23.8525
2024-09-30Goldman Sachs Group Inc1.15140.001935036415582580.0996
2024-09-30Cormorant Asset Management, LLC1.12550.60843424653424650
2024-09-30Millennium Management LLC1.08960.0053331566-42196-11.2895
2024-09-30Federated Hermes Inc1.04260.0233317243281186779.8375
Total 82.062925.853224970639+2825737+11.3%

4.9.2. Funds holding AnaptysBio Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-10-31Vanguard Total Stock Mkt Idx Inv2.4120.0009733946-5-0.0007
2024-08-31Fidelity Small Cap Growth2.05450.3111625155-1635-0.2609
2024-06-30Eventide Healthcare & Life Sciences I1.86770.988256832414132433.097
2024-09-30FIAM Small Cap Core CIT Cl B1.80030.3704547800-20200-3.5563
2024-11-27iShares Russell 2000 ETF1.77960.0169541523-1134-0.209
2024-06-30FIAM Small Cap Core Composite1.48170.24874508494508490
2024-11-27SPDR® S&P Biotech ETF1.39350.1435424027-12870-2.9458
2024-09-30Fidelity Advisor Biotechnology I1.39050.753442310000
2024-08-31Fidelity Series Small Cap Opps1.26990.2592386400-16800-4.1667
2024-09-30T. Rowe Price Health Sciences1.20880.07973678207418025.2622
2024-09-30Fidelity Select Biotechnology1.12250.23113415726610023.9952
2024-09-30T. Rowe Price New Horizons1.05860.05073221225676621.3924
2024-09-30US Small-Cap Growth II Equity Comp1.05860.05073221223221220
2024-10-31Vanguard Institutional Extnd Mkt Idx Tr0.98410.006299461-1084-0.3607
2024-10-31Vanguard Small Cap Index0.8720.00382653335000.1888
2024-08-31Fidelity Stock Selector Small Cap0.86230.258526240057002.2205
2024-08-31Fidelity Small Cap Growth K60.79150.298424084524451.0256
2024-10-31Franklin Biotechnology Discv A(acc)USD0.74070.318222537600
2024-09-30Fidelity Small Cap Index0.65040.0242197918-1087-0.5462
2024-11-27iShares Russell 2000 Growth ETF0.58360.033417757700
Total 25.38284.4477723670+1065171+13.8%

5.3. Insider Transactions

Insiders are holding 1.738% of the shares of AnaptysBio Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-09-23Paul F LizzulSELL150038.67
2024-09-16Dennis MulroySELL1222039.91
2024-09-16Eric J LoumeauSELL872039.82
2024-08-14Ecor1 Capital, LlcBUY27397236.5
2024-07-18Paul F LizzulSELL150035
2024-07-15Hollings RentonSELL1000030.64
2024-06-21Dennis M FentonSELL195023.17
2024-06-18Hollings RentonSELL195023.16
2024-05-22Dennis MulroySELL150023.72
2024-03-25Daniel FagaSELL300021.42
2024-03-22Daniel FagaSELL14594022.78
2024-02-16Eric J LoumeauSELL500025
2024-01-30Dennis MulroySELL306523.63
2024-01-08Daniel FagaSELL686621.81
2024-01-08Dennis MulroySELL218021.81
2024-01-08Paul F LizzulSELL255421.81
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2023-09-302023-12-312024-03-312024-06-302024-09-30
Inventory  0000000-12,195-12,195
Accumulated Other Comprehensive Income  -2,3501,553-797173-624209-4151,174759
Income Tax Expense  4,4324424,874-4,312562-5539-605-596



5.2. Latest Balance Sheet

Balance Sheet of 2024-09-30. Currency in USD. All numbers in thousands.

Summary
Total Assets493,418
Total Liabilities409,051
Total Stockholder Equity84,367
 As reported
Total Liabilities 409,051
Total Stockholder Equity+ 84,367
Total Assets = 493,418

Assets

Total Assets493,418
Total Current Assets448,681
Long-term Assets44,737
Total Current Assets
Cash And Cash Equivalents 191,581
Short-term Investments 238,536
Net Receivables 12,195
Other Current Assets 6,369
Total Current Assets  (as reported)448,681
Total Current Assets  (calculated)448,681
+/-0
Long-term Assets
Property Plant Equipment 16,567
Long Term Investments 27,914
Long-term Assets Other 256
Long-term Assets  (as reported)44,737
Long-term Assets  (calculated)44,737
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities43,880
Long-term Liabilities365,171
Total Stockholder Equity84,367
Total Current Liabilities
Short-term Debt 3,774
Accounts payable 3,592
Other Current Liabilities 36,514
Total Current Liabilities  (as reported)43,880
Total Current Liabilities  (calculated)43,880
+/-0
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt12,720
Long-term Liabilities Other 350,564
Long-term Liabilities  (as reported)365,171
Long-term Liabilities  (calculated)363,284
+/- 1,887
Total Stockholder Equity
Common Stock30
Retained Earnings -737,543
Accumulated Other Comprehensive Income 759
Other Stockholders Equity 821,121
Total Stockholder Equity (as reported)84,367
Total Stockholder Equity (calculated)84,367
+/-0
Other
Capital Stock30
Cash and Short Term Investments 430,117
Common Stock Shares Outstanding 28,893
Liabilities and Stockholders Equity 493,418
Net Debt -175,087
Net Invested Capital 84,367
Net Working Capital 404,801
Property Plant and Equipment Gross 23,037
Short Long Term Debt Total 16,494



5.3. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302013-12-31
> Total Assets 
3,914
0
25,065
0
22,291
60,877
56,280
54,723
58,498
55,837
62,180
131,111
130,409
121,945
329,364
314,837
306,017
523,121
508,997
494,226
480,149
451,505
435,197
424,233
401,746
384,750
416,552
396,418
426,569
424,335
643,070
625,171
603,848
618,503
610,383
551,792
517,100
487,326
452,389
405,835
427,376
493,418
493,418427,376405,835452,389487,326517,100551,792610,383618,503603,848625,171643,070424,335426,569396,418416,552384,750401,746424,233435,197451,505480,149494,226508,997523,121306,017314,837329,364121,945130,409131,11162,18055,83758,49854,72356,28060,87722,291025,06503,914
   > Total Current Assets 
0
0
24,401
0
21,077
58,240
53,464
51,379
55,090
52,352
58,208
110,155
115,848
120,327
252,696
251,945
271,819
503,022
434,216
421,942
430,988
424,597
377,733
371,055
384,516
345,814
396,561
387,131
398,061
386,644
553,876
512,411
452,809
450,444
447,205
437,154
438,535
428,000
406,835
372,420
367,350
448,681
448,681367,350372,420406,835428,000438,535437,154447,205450,444452,809512,411553,876386,644398,061387,131396,561345,814384,516371,055377,733424,597430,988421,942434,216503,022271,819251,945252,696120,327115,848110,15558,20852,35255,09051,37953,46458,24021,077024,40100
       Cash And Cash Equivalents 
2,810
0
22,188
0
16,894
55,245
51,684
49,318
50,586
47,134
51,232
96,754
30,752
26,669
81,189
69,474
57,057
293,408
113,596
105,853
146,552
182,898
171,017
165,317
221,172
209,154
250,456
284,148
332,254
336,328
495,729
166,412
71,701
58,547
71,308
94,562
35,206
26,295
35,965
53,695
71,821
191,581
191,58171,82153,69535,96526,29535,20694,56271,30858,54771,701166,412495,729336,328332,254284,148250,456209,154221,172165,317171,017182,898146,552105,853113,596293,40857,05769,47481,18926,66930,75296,75451,23247,13450,58649,31851,68455,24516,894022,18802,810
       Short-term Investments 
0
0
0
0
0
0
0
0
6,742
6,742
0
6,742
75,607
89,053
167,218
178,691
210,852
200,406
313,486
309,812
275,664
238,104
203,210
197,166
156,706
129,192
143,197
96,212
58,597
37,736
52,368
339,209
370,450
384,419
369,933
336,589
394,280
386,752
354,939
300,970
278,983
238,536
238,536278,983300,970354,939386,752394,280336,589369,933384,419370,450339,20952,36837,73658,59796,212143,197129,192156,706197,166203,210238,104275,664309,812313,486200,406210,852178,691167,21889,05375,6076,74206,7426,74200000000
       Net Receivables 
0
0
1,455
0
2,757
1,913
1,226
1,191
3,578
4,153
5,343
4,965
5,637
1,486
1,601
1,610
152
5,173
174
175
5,000
0
0
5,000
0
0
0
1,247
642
761
876
921
1,033
1,180
1,419
1,523
3,182
3,269
6,851
7,089
9,007
12,195
12,1959,0077,0896,8513,2693,1821,5231,4191,1801,0339218767616421,2470005,000005,0001751745,1731521,6101,6011,4865,6374,9655,3434,1533,5781,1911,2261,9132,75701,45500
       Inventory 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
60
60
60
-876
0
0
0
0
0
0
0
0
0
0
-12,195
-12,1950000000000-876606060000000000000000000000000000
   > Long-term Assets 
0
0
664
0
1,214
2,637
2,816
3,344
3,408
3,485
3,972
20,956
14,561
1,618
76,668
62,892
34,198
20,099
74,781
72,284
49,161
26,908
57,464
53,178
17,230
38,936
19,991
9,287
28,508
37,691
89,194
112,760
151,039
168,059
163,178
114,638
78,565
59,326
45,554
33,415
60,026
44,737
44,73760,02633,41545,55459,32678,565114,638163,178168,059151,039112,76089,19437,69128,5089,28719,99138,93617,23053,17857,46426,90849,16172,28474,78120,09934,19862,89276,6681,61814,56120,9563,9723,4853,4083,3442,8162,6371,214066400
       Property Plant Equipment 
750
0
579
0
588
564
551
536
483
425
471
569
543
513
665
659
1,086
1,344
1,445
1,584
1,481
1,695
1,618
1,610
1,495
1,585
1,783
1,754
22,766
22,191
21,841
21,309
20,798
20,292
19,987
19,453
19,070
18,867
18,272
17,686
17,124
16,567
16,56717,12417,68618,27218,86719,07019,45319,98720,29220,79821,30921,84122,19122,7661,7541,7831,5851,4951,6101,6181,6951,4811,5841,4451,3441,08665966551354356947142548353655156458805790750
       Long Term Investments 
0
0
0
0
0
0
0
0
20,327
20,327
0
20,327
13,912
999
75,897
61,884
32,730
18,616
73,128
68,551
45,707
23,418
54,305
50,215
14,321
36,177
17,546
7,056
5,484
15,242
67,097
91,195
129,985
147,511
142,935
94,929
59,239
40,203
27,026
15,473
42,646
27,914
27,91442,64615,47327,02640,20359,23994,929142,935147,511129,98591,19567,09715,2425,4847,05617,54636,17714,32150,21554,30523,41845,70768,55173,12818,61632,73061,88475,89799913,91220,327020,32720,32700000000
       Long-term Assets Other 
0
0
85
0
626
2,073
2,265
2,808
2,925
3,060
3,501
60
106
106
106
349
382
139
208
2,149
1,973
1,795
1,541
1,353
1,414
1,174
662
477
258
258
256
256
256
256
256
256
256
256
256
256
256
256
2562562562562562562562562562562562562582584776621,1741,4141,3531,5411,7951,9732,149208139382349106106106603,5013,0602,9252,8082,2652,07362608500
> Total Liabilities 
3,769
0
19,072
0
16,438
15,296
13,943
12,944
14,102
11,080
22,912
20,996
21,234
20,590
21,783
20,310
21,038
23,444
22,632
26,071
31,728
30,613
30,189
23,669
20,310
24,507
19,821
14,475
40,838
40,727
286,642
294,424
299,542
340,884
348,280
360,699
368,650
366,943
364,286
358,057
417,497
409,051
409,051417,497358,057364,286366,943368,650360,699348,280340,884299,542294,424286,64240,72740,83814,47519,82124,50720,31023,66930,18930,61331,72826,07122,63223,44421,03820,31021,78320,59021,23420,99622,91211,08014,10212,94413,94315,29616,438019,07203,769
   > Total Current Liabilities 
3,162
0
11,681
0
10,479
9,643
7,376
7,114
8,829
7,539
5,708
8,126
10,079
11,174
14,090
14,343
16,790
20,873
21,836
24,754
30,623
29,730
29,535
23,250
20,130
24,474
19,821
14,475
20,616
20,889
16,099
19,781
19,871
21,063
26,054
35,795
41,631
39,178
37,442
32,298
40,420
43,880
43,88040,42032,29837,44239,17841,63135,79526,05421,06319,87119,78116,09920,88920,61614,47519,82124,47420,13023,25029,53529,73030,62324,75421,83620,87316,79014,34314,09011,17410,0798,1265,7087,5398,8297,1147,3769,64310,479011,68103,162
       Short-term Debt 
0
0
129
0
769
1,151
21
407
996
1,596
1
1,250
3,125
5,013
6,892
7,522
7,527
7,548
7,632
7,282
5,600
3,922
2,246
898
925
851
342
197
555
1,097
1,505
1,537
1,570
1,604
1,637
1,671
1,706
1,741
3,554
1,813
3,700
3,774
3,7743,7001,8133,5541,7411,7061,6711,6371,6041,5701,5371,5051,0975551973428519258982,2463,9225,6007,2827,6327,5487,5277,5226,8925,0133,1251,25011,596996407211,151769012900
       Short Long Term Debt 
0
0
4,793
0
0
0
4,903
0
985
1,590
13,809
1,250
14,112
5,000
6,875
7,500
7,500
7,500
7,574
6,488
4,781
3,077
1,375
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000001,3753,0774,7816,4887,5747,5007,5007,5006,8755,00014,1121,25013,8091,59098504,9030004,79300
       Accounts payable 
197
0
415
0
765
1,561
1,521
663
2,060
1,440
2,278
2,546
3,724
2,557
2,323
2,416
4,426
6,180
5,443
9,072
10,921
10,522
16,237
8,571
6,289
5,484
4,217
2,452
4,103
5,717
1,741
2,481
1,587
3,006
2,784
3,168
4,761
6,521
4,698
4,582
4,890
3,592
3,5924,8904,5824,6986,5214,7613,1682,7843,0061,5872,4811,7415,7174,1032,4524,2175,4846,2898,57116,23710,52210,9219,0725,4436,1804,4262,4162,3232,5573,7242,5462,2781,4402,0606631,5211,56176504150197
       Other Current Liabilities 
2,147
0
1,052
0
1,550
2,161
2,892
2,779
2,890
2,974
1
4,330
3,230
13
17
22
27
48
58
794
819
845
871
898
925
851
15,262
11,826
15,958
14,075
11,348
15,763
16,714
16,453
21,633
30,956
35,164
30,916
29,190
25,903
31,830
36,514
36,51431,83025,90329,19030,91635,16430,95621,63316,45316,71415,76311,34814,07515,95811,82615,2628519258988718458197945848272217133,2304,33012,9742,8902,7792,8922,1611,55001,05202,147
   > Long-term Liabilities 
0
0
7,391
0
5,959
5,653
6,567
5,830
5,273
3,541
17,204
12,870
11,155
9,416
7,693
5,967
4,248
2,571
796
1,317
1,105
883
654
419
180
33
0
0
20,222
19,838
270,543
274,643
279,671
319,821
322,226
324,904
327,019
327,765
326,844
325,759
377,077
365,171
365,171377,077325,759326,844327,765327,019324,904322,226319,821279,671274,643270,54319,83820,22200331804196548831,1051,3177962,5714,2485,9677,6939,41611,15512,87017,2043,5415,2735,8306,5675,6535,95907,39100
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
12,709
10,987
9,269
7,553
5,834
4,120
2,409
625
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000006252,4094,1205,8347,5539,26910,98712,70900000000000
       Capital Lease Obligations Min Short Term Debt
0
0
-129
0
-769
-1,151
-21
-407
-996
-1,596
-1
-1,250
-3,125
-5,013
-6,892
-7,522
-7,527
-7,548
-7,632
-7,282
-5,600
-3,922
-2,246
0
0
33
0
0
20,222
19,838
19,450
19,059
18,652
18,235
17,813
17,388
16,946
16,493
14,260
15,575
13,246
12,720
12,72013,24615,57514,26016,49316,94617,38817,81318,23518,65219,05919,45019,83820,222003300-2,246-3,922-5,600-7,282-7,632-7,548-7,527-7,522-6,892-5,013-3,125-1,250-1-1,596-996-407-21-1,151-7690-12900
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
0
0
161
168
147
140
133
128
162
171
1,317
1,105
883
654
419
180
33
0
0
0
0
251,093
255,584
261,019
301,586
304,413
307,516
310,073
311,272
310,807
310,184
361,981
350,564
350,564361,981310,184310,807311,272310,073307,516304,413301,586261,019255,584251,0930000331804196548831,1051,31717116212813314014716816100000000000
       Deferred Long Term Liability 
0
0
2,029
0
0
0
2,205
0
138
148
3,441
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000000000003,44114813802,2050002,02900
> Total Stockholder Equity
145
0
5,993
0
5,853
45,581
42,337
41,779
44,396
44,757
39,268
110,115
109,175
101,355
307,581
294,527
284,979
499,677
486,365
468,155
448,421
420,892
405,008
400,564
381,436
360,243
396,731
381,943
385,731
383,608
356,428
330,747
304,306
277,619
262,103
191,093
148,450
120,383
88,103
47,778
9,879
84,367
84,3679,87947,77888,103120,383148,450191,093262,103277,619304,306330,747356,428383,608385,731381,943396,731360,243381,436400,564405,008420,892448,421468,155486,365499,677284,979294,527307,581101,355109,175110,11539,26844,75744,39641,77942,33745,5815,85305,9930145
   Common Stock
17
0
17
0
18
18
3
18
18
14
3
20
20
20
24
24
24
27
27
27
27
27
27
27
27
27
27
27
27
27
28
28
28
28
29
27
27
27
27
27
27
30
30272727272727292828282827272727272727272727272727242424202020314181831818017017
   Retained Earnings Total Equity00000-534,577-494,732-450,477-424,064-390,562-358,008-321,753-289,215-282,549-282,120-263,957-297,603-273,836-252,288-244,026-223,763-192,730-168,768-146,690-129,696-113,738-100,100-85,000-78,173-69,083-66,40000000000000
   Accumulated Other Comprehensive Income 
0
0
-3,355
0
-3,497
-3,560
-3,583
-3,640
-3,700
-3,758
-3,798
-13
-59
-43
-426
-801
-677
-541
-223
204
574
480
338
1,145
753
259
-4
-111
-176
-200
-422
-2,434
-3,861
-6,007
-5,246
-3,267
-3,611
-2,350
-797
-624
-415
759
759-415-624-797-2,350-3,611-3,267-5,246-6,007-3,861-2,434-422-200-176-111-42597531,145338480574204-223-541-677-801-426-43-59-13-3,798-3,758-3,700-3,640-3,583-3,560-3,4970-3,35500
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
176,507
178,297
179,551
393,017
395,424
399,370
629,887
633,251
636,692
640,550
644,148
648,669
651,680
654,492
657,560
660,665
664,147
668,429
672,996
678,575
691,161
698,701
707,662
717,797
689,065
686,611
0
0
0
0
0
00000686,611689,065717,797707,662698,701691,161678,575672,996668,429664,147660,665657,560654,492651,680648,669644,148640,550636,692633,251629,887399,370395,424393,017179,551178,297176,50700000000000
   Treasury Stock000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
17,762
0
18,194
18,759
19,065
19,437
19,792
98,846
20,470
45,396
47,888
57,606
393,017
80,587
93,353
106,766
633,251
636,692
640,550
644,148
648,669
651,680
654,492
657,560
660,665
664,147
668,429
672,996
678,575
691,161
698,701
707,662
717,797
689,065
686,611
694,591
702,969
706,407
714,959
821,121
821,121714,959706,407702,969694,591686,611689,065717,797707,662698,701691,161678,575672,996668,429664,147660,665657,560654,492651,680648,669644,148640,550636,692633,251106,76693,35380,587393,01757,60647,88845,39620,47098,84619,79219,43719,06518,75918,194017,76200



5.4. Balance Sheets

Currency in USD. All numbers in thousands.




5.5. Cash Flows

Currency in USD. All numbers in thousands.




5.6. Income Statements

Currency in USD. All numbers in thousands.